Clinical Research Directory
Browse clinical research sites, groups, and studies.
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)
Sponsor: Novartis Pharmaceuticals
Summary
This was Cohort B2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
Official title: A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Participants With Uncomplicated Plasmodium Falciparum Malaria
Key Details
Gender
All
Age Range
12 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2024-01-23
Completion Date
2025-03-19
Last Updated
2026-05-07
Healthy Volunteers
No
Interventions
KAE609
oral capsules administered in combination with KLU156
SoC (Coartem)
Standard of Care
KLU156
oral sachet formulation (KAF156+LUM-SDF) administered in combination with cipargamin (KAE609)
Locations (3)
Novartis Investigative Site
Abidjan, Côte d’Ivoire
Novartis Investigative Site
Libreville, Gabon
Novartis Investigative Site
Ahero, Kenya